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ABSTRACT Aspergillus fumigatus is a ubiquitous opportunistic pathogen. This fun-
gus can acquire resistance to azole antifungals due to mutations in the azole target
(cyp51A). Recently, cyp51A mutations typical for environmental azole resistance ac-
quisition (for example, TR34/L98H) have been reported. These mutations can also be
found in isolates recovered from patients. Environmental azole resistance acquisition
has been reported on several continents. Here we describe, for the ﬁrst time, the oc-
currence of azole-resistant A. fumigatus isolates of environmental origin in Switzer-
land with cyp51A mutations, and we show that these isolates can also be recovered
from a few patients. While the TR34/L98H mutation was dominant, a single azole-
resistant isolate exhibited a cyp51A mutation (G54R) that was reported only for clini-
cal isolates. In conclusion, our study demonstrates that azole resistance with an envi-
ronmental signature is present in environments and patients of Swiss origin and
that mutations believed to be unique to clinical settings are now also observed in
the environment.
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Aspergillus fumigatus is a common and widespread ﬁlamentous fungus. A. fumigatuscan disperse easily in the environment due to its ability to form conidia. Due to
their small diameter, conidia can easily reach the lower respiratory airways of humans.
This characteristic makes A. fumigatus a cause of several pulmonary diseases in humans,
ranging from aspergilloma to allergic bronchopulmonary aspergillosis (ABPA) and
various forms of invasive aspergillosis (IA) (1). The treatment of aspergillosis syndrome
involves four triazole antifungal drugs: itraconazole (ITZ), voriconazole (VRZ), posacona-
zole (POS), and isavuconazole (ISA). ITZ was the ﬁrst orally active drug for aspergillosis
(2). VRZ was approved next and showed its superiority to amphotericin B (3). The oral
and intravenous availability of VRZ and its positive effects on patients made this drug
the ﬁrst choice for IA in almost all clinical guidelines (4). POS was approved later for the
prevention of fungal infection (especially aspergillosis) in leukemia and bone marrow
transplant patients and for second-line therapy (5). ISA has been approved more
recently for the treatment of IA (6).
The use of antifungal agents is inevitably associated with the occurrence of resis-
tance. After azoles were introduced to treat A. fumigatus infections, reports of resistance
started to emerge. The ﬁrst case of azole-resistant A. fumigatus reported involved a
mutation in the cyp51A gene, the target of azoles in this organism. This isolate revealed
a single mutation in which methionine at the codon position 220 was replaced by
arginine (M220R). A similar mutation, M220I, was recovered from a Swedish patient in
1998. Since then, several other single substitutions in cyp51A have been identiﬁed (7).
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Single substitutions at codons G54, G138, P216, F219, M220, and G448 have been
reported (8). In 2007, Mellado et al. (9) identiﬁed a novel type of mutation in several
pan-azole-resistant clinical isolates associating a single amino acid substitution in
cyp51A with a 34-bp tandem repeat in the promoter of the same gene (the TR34/L98H
mutation). This type of mutation was next found in the environment, raising the
possibility that agricultural azole use could facilitate the dissemination of such resistant
strains (10). The TR34/L98H mutation has now been reported at the scale of several
continents (11). In addition, the presence of another mutation, TR46/Y121F/T289A, has
also been reported in six of nine European countries (12).
Epidemiological data gathered to date show that the frequency of environmental
resistance acquisition ranges from 0.5 to 5% in sampled isolates (10). The prevalence of
azole resistance in the clinic differs depending on population type and origin, ranging
from 4 to 16% (11, 13).
Reports of A. fumigatus azole resistance in Switzerland are rare. A prospective study
launched between 2001 and 2003 addressed the occurrence of azole resistance in
isolates from clinical and environmental samples. Among the isolates recovered (n 
550), only two exhibited ITZ resistance (14, 15). This result was obtained with a neutral
selection of isolates from available samples, which were systematically analyzed for
azole susceptibility. We report here a novel study in which isolates were recovered from
clinical and environmental samples from a small geographical area in Switzerland.
Samples were analyzed for the presence of azole-resistant isolates by a widely used
positive-selection procedure. Following this, screening for azole-resistant A. fumigatus
was implemented at the Geneva University Hospital (HUG), and as a result, two strains
of A. fumigatus with TR34/L98H were identiﬁed in two different patients with cystic
ﬁbrosis (CF).
RESULTS
Environmental isolates. Sixty-four samples of different environmental origins com-
prising a variety of sources (compost sites, public/private gardens, vineyard and agri-
culture soils, and commercial soil samples) were collected in the western part of
Switzerland (the region of Geneva, Lausanne, and Neuchâtel) in a 4-month period
(August to December 2015) (see Table S1 in the supplemental material). Six of the 64
samples (9.3%) showed the growth of A. fumigatus colonies on Sabouraud dextrose
agar with 4 g/ml ITZ (SabITZ); 5 A. fumigatus isolates (5d, 15a, 15f, 37c, and 50a) from
these samples were VIPcheck positive, conﬁrming that they were ITZ and VRZ resistant.
The isolates were further analyzed by matrix-assisted laser desorption ionization—time
of ﬂight (MALDI-TOF) mass spectrometry (MS) to conﬁrm their species assignment, and
all were identiﬁed as A. fumigatus. Susceptibility testing of the A. fumigatus isolates was
next performed (by the Sensititre YeastOne [SYO] and CLSI methods) and showed
distinct patterns of resistance (Table 1). While all the isolates but one (isolate 61) were
TABLE 1 Characteristics of A. fumigatus isolates of this study
Isolate Origin Sample type
MIC (g/ml) by:
cyp51A mutation CSP1 type
YeastOne Sensititre
test CLSI M38 method
ITZ VRZ POS ITZ VRZ POS
5d Environment Commercial vineyard soil mix 16 0.25 1 16 0.25 2 G54R t01
15a Environment Compost sample 16 8 1 16 2 1 TR34/L98H t02
15f Environment Compost sample 16 4 0.25 16 4 1 TR34/L98H t11
37c Environment Compost sample 16 2 0.25 16 2 1 TR34/L98H t02
50a Environment Soil sample 16 4 0.25 16 2 1 TR34/L98H t02
61 Environment Commercial soil sample 1 0.5 0.125 1 0.5 0.25 TR34/L98H t03
37a Environment Compost sample 0.25 0.25 0.06 0.25 0.25 0.125 WTa t03
20089320 Patient Bronchoalveolar lavage ﬂuid 16 2 0.25 16 4 1 TR34/L98H t02
17993925 Patient Bronchoalveolar lavage ﬂuid 16 4 0.25 16 4 1 TR34/L98H t01
aWT, wild type.
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ITZ resistant (MIC, 16 g/ml), the VRZ and POS MICs differed. One isolate (5d) stood
out, since it was still susceptible to VRZ (Table 1). Isolate 61 exhibited an ITZ MIC that
was low (1 g/ml) but still higher than that of a susceptible control (isolate 37a, with
a MIC of 0.25 g/ml). The cyp51A gene and its promoter region from these isolates were
sequenced to support the antifungal susceptibility results. The sequences obtained
were identical to published A. fumigatus cyp51A sequences. These data and separate
-tubulin sequencing (data not shown) thus conﬁrmed that the isolates belonged to A.
fumigatus sensu stricto. As summarized in Table 1, the majority of azole-resistant isolates
harbored the TR34/L98H mutation. The exception was isolate 5d, with a G54R substi-
tution in cyp51A. CLSI MIC readings supported the values obtained by the SYO method
with two exceptions. Isolate 5d exhibited a VRZ MIC value of 8 g/ml by the SYO test
but 2 g/ml by the CLSI method. POS MIC values were, in general, higher for some
isolates by the CLSI method (1 g/ml) than by the SYO test (in the range of 0.25 g/ml),
which, however, still categorized these isolates as POS resistant.
Clinical isolates. Given the detection of azole-resistant isolates in the environment,
it was decided to prospectively screen A. fumigatus isolates from clinical samples (160
isolates) (see Table S2 in the supplemental material) for azole resistance at the Univer-
sity Hospital of Geneva during a period of about 1 year (2016–2017). We identiﬁed two
azole-resistant isolates in the sputum samples of CF patients (see case descriptions
below). These isolates exhibited ITZ, VRZ, and POS resistance (MICs, 16 g/ml,
4 g/ml, and 0.25 g/ml, respectively). Sequencing analysis of cyp51A and -tubulin
revealed that both isolates exhibited the TR34/L98H mutation; they were classiﬁed as A.
fumigatus sensu stricto.
CSP1 typing. The CSP1 gene encodes a cell surface protein that is involved in the
conidial germination process and in adherence to the extracellular matrix (16). Klaassen
and colleagues used CSP1 in order to categorize A. fumigatus strains (17). The typing
nomenclature is based on repeat regions found in CSP1, which are classiﬁed into 18
CSP1 types. It has been suggested that CSP typing, with a lower discriminatory power
than microsatellite analysis, is suitable for typing at the subpopulation level (16). We
addressed the relationships among our sampled isolates by this method. CSP1 typing
of all isolates showed four different CSP1 types: the TR34/L98H isolates were distributed
over the t01, t02, t03, and t11 subtypes, while the G54R isolate belonged to the t01
subtype (Table 1). The azole-susceptible isolate of environmental origin included here
belonged to CSP1 subtype t03.
DISCUSSION
A. fumigatus harboring the TR34/L98H mutation, leading to panazole resistance, was
ﬁrst described in the Netherlands in 2008, followed by other countries (7, 12). The
overuse of azoles in agriculture was proposed to be the route of selective pressure on
A. fumigatus to develop resistance. In addition, Snelders et al. (18) showed by micro-
satellite typing that cyp51A mutant strains recovered from the environment and from
clinical samples clustered together. This likely indicates common ancestors for the two
groups of isolates.
The results presented here conﬁrmed previous ﬁndings on the occurrence of azole
resistance in A. fumigatus (19). Our study conﬁrms the presence of isolates with the
TR34/L98H mutation in the environment in the western part of Switzerland. Interest-
ingly, a single substitution mutation (G54R) was detected in an environmental A. fumigatus
isolate. Mutations at position G54 are known to be the consequence of long-term azole
therapy in patients (19). Two recent publications have also shown the presence of single
substitutions in cyp51A from environmental isolates. The G54E mutation was reported for
isolates from environmental samples in Romania, India, and Tanzania, and a novel substi-
tution, G54A, was reported in Germany (20, 21). Since the selective agar medium SabITZ
contains 4 g/ml ITZ, the selection of resistant isolates for which MICs are higher than this
concentration can be expected. The TR34/L98H and G54R mutations result effectively in
high ITZ MICs (16 g/ml). The type of cyp51A mutation has a differential impact on VRZ
MICs: while the TR34/L98H mutation invariably results in VRZ resistance (all isolates exhibit
A. fumigatus Azole Resistance Antimicrobial Agents and Chemotherapy
April 2018 Volume 62 Issue 4 e02088-17 aac.asm.org 3
MIC values of 2 g/ml), the G54R mutation does not result in VRZ resistance (MIC, 0.25
g/ml). Interestingly, Bader and colleagues showed that a selective agar medium with a
lower ITZ concentration (1 g/ml) could identify a broader spectrum of mutations (i.e.,
TR46/Y121F/T289A and TR46/Y121F/M172I/T289A), which are associated with a lower ITZ
MIC (2g/ml) but with the same VRZ and POSMICs (21). Even though themost prevalent
environmental mutation is TR34/L98H, the detection of other cyp51A mutations is impor-
tant. Therefore, the choice of an appropriate selective medium will have a direct
impact on the screening of resistance in A. fumigatus.
Susceptibility testing was performed by two methods, which agreed with each other
for most recorded values. POS MICs for TR34/L98H isolates were, in general, higher by
the CLSI method than by the SYO test. This difference could be due to endpoint reading
issues in the SYO approach, which is based on a change in the color of the metabolic
indicator (alamarBlue) rather than on visual inspection of turbidity as performed in the
CLSI method. Our antifungal susceptibility testing results were comparable to those of
previous studies except for one isolate. This particular isolate (isolate 61), with an ITZ
MIC of 1 g/ml by both methods, was interpreted as susceptible according to the CLSI
breakpoints. These results reveal that the TR34/L98H mutation is not always correlated
with panazole resistance, a pattern consistent with that of a previous study in which the
occurrence of TR34/L98H was not strictly associated with ITZ resistance (MIC cutoff,
1 g/ml) (22). Therefore, the azole susceptibility proﬁle could not be inferred from the
detection of the TR34/L98H mutation alone.
In order to assess the relationships among azole-resistant A. fumigatus isolates, two
genotyping methods have generally been applied: microsatellite (STRAf) genotyping
and CSP1 typing. We identiﬁed CSP1 types (t02 and t011) that had already been
reported for azole-resistant isolates (21). A. fumigatus isolate 5d (G54R) had CSP1 type
t01, which was also associated with a G54W mutation in the study of Bader et al. (21).
However, there seems to be no strict association of the CSP1 type with the occurrence
of resistance, since CSP type t01 is also found in wild-type isolates (17). In any case, the
small number of azole-resistant A. fumigatus isolates in our study cannot support the
conclusion that these isolates have a common origin.
The presence of azole-resistant A. fumigatus isolates from patients has been mon-
itored in different parts of the world with different levels of prevalence (23). In 2015,
Switzerland participated in the SCARE study (23) using isolates originating from a single
hospital center (University of Lausanne). Among the 236 isolates tested, none exhibited
azole resistance (23). An older study performed in Switzerland using A. fumigatus isolates
mostly from CF patients (n 400) but originating from different institutions (all before the
year 2003) reported a single ITZ-resistant isolate, which was devoid of the TR34/L98H
mutation (15). The present study reveals, for the ﬁrst time in Switzerland, pan-azole-
resistant A. fumigatus isolates from CF patients. One particularly noteworthy point was that
the records of these patients did not report the use of azoles. This suggests that the source
of the azole-resistant isolates may be environmental. This hypothesis was already sug-
gested in a study investigating A. fumigatus azole resistance in CF patients, some of whom
were colonized with azole-resistant isolates without prior azole treatment (24).
The isolation of azole-resistant isolates in the Swiss environment is not a surprise
per se, given that most European countries have reported the same phenomenon. The
worldwide occurrence of azole resistance in A. fumigatus poses several issues, one of
which is the management of patients with prior colonization by resistant isolates. Such
patients should be identiﬁed early enough for the rapid adaptation of antifungal
therapy. Continuing surveillance of azole resistance should also be more systematically
organized in Switzerland than it is currently (absence of surveillance program), and the
medical sector should be kept well informed on the progression of resistance at a
nation-wide scale.
MATERIALS AND METHODS
Environmental samples. Sixty-four samples collected from different environments in the Le-
manic region (Table S1 in the supplemental material) were positively screened for A. fumigatus ITZ
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resistance using a Sabouraud dextrose agar plate (2%; Becton, Dickinson [BD] Difco) supplemented with
ITZ at 4 g/ml (SabITZ) (Sigma-Aldrich). Each sample was treated as follows before the azole resistance
screening procedure. A 1- to 2-g portion of each sample was suspended in an 8-ml solution containing
sterile water, 1% Tween 20 (Sigma-Aldrich), and 0.5 g/liter chloramphenicol (Sigma-Aldrich) (25). Each
sample was vortexed for 1 min and was then sedimented for 3 h at room temperature according to
published recommendations (25). One hundred microliters of the supernatant from the sedimented
solution was plated on two Sabouraud dextrose agar plates (2%; BD Difco) and two SabITZ plates
(Sigma-Aldrich). The plates were incubated at 37°C for 72 h and were checked for the growth of
Aspergillus complex spp. Fungal colonies isolated on SabITZ and Sabouraud agar plates were analyzed
with a Microﬂex LT MALDI-TOF MS (Bruker Daltonics) and were identiﬁed as A. fumigatus complex with
Biotyper software, version 3.0, using the Filamentous Fungi Library, version 1.0 (Bruker Daltonics).
Colonies growing on SabITZ were next screened for resistance using the VIPcheck test, which consists of
a 4-well plate containing agar supplemented with three azole drugs (VRZ at 2 g/ml, ITZ at 4 g/ml, and
POS at 0.5 g/ml) and a growth control. The plates were incubated at 37°C for 72 h. A. fumigatus isolates
with growth on SabITZ and the VIPcheck test were tested for their susceptibility proﬁles.
Clinical samples. A. fumigatus group species isolated from respiratory samples of CF patients
collected mostly during the year 2016–2017 (Table S2 in the supplemental material) were tested for
azole resistance. Each isolate was recovered from 80°C stocks and was grown on Sabouraud maltose
agar. The azole resistance pattern was phenotypically tested using the VIPcheck method. Identiﬁcation
of ﬁlamentous fungi was carried out on the Microﬂex LT MALDI-TOF MS (Bruker Daltonics).
Susceptibility testing. A. fumigatus isolates harboring phenotypic resistance to an azole(s) were
tested for their susceptibility proﬁles by the standardized colorimetric microdilution test method,
Sensititre YeastOne (SYO) (Thermo Scientiﬁc). The test yields MICs for 10 antifungal agents, including ITZ,
VRZ, POS, ﬂuconazole, caspofungin, micafungin, anidulafungin, ﬂucytosine, and amphotericin B. The test
was performed according to the manufacturer’s instructions. Brieﬂy, 100 l from a 0.5 McFarland
standard inoculum of A. fumigatus was added to the SYO broth, which contains RPMI medium 1640
(Thermo Scientiﬁc), and was vortexed; then 100 l of the SYO broth was added to each of the 96 wells
of the SYO plate. The SYO plate was incubated at 37°C for 48 to 72 h. MICs were determined by changes
in the color of alamarBlue as an indicator of metabolic activity.
The susceptibility of A. fumigatus isolates was also determined according to the CLSI M38-A2 method
(26). The MIC was deﬁned as the antifungal concentration at which visual growth was completely
inhibited. The isolate was regarded as susceptible when the MIC was 2 g/ml for ITZ and VRC and
0.25 g/ml for POS, according to the recommendations of Espinel-Ingroff et al. (27). An isolate
containing the known cyp51A TR34/L98H mutation (CM2627) was included as a control in susceptibility
assays (9).
Sequencing. Isolates with a phenotypic resistance pattern were sequenced for the cyp51A gene. A.
fumigatus DNA was extracted using a one-step procedure. The fungal biomass was added to a
microcentrifuge tube containing 0.3 g of glass beads (diameter, 0.5 mm), 200 l phenol-chloroform
(Sigma), and 200 l of breaking buffer (2% Triton X-100, 1% sodium dodecyl sulfate, 10 mM Tris-HCl [pH
8.0], 1 mM EDTA, 100 mM NaCl). After 15 s of shaking at 4,500 rpm using a Precellys Evolution tissue
homogenizer (Bertin Instruments, France), samples were centrifuged for 10 min at 13,000 rpm. One
microliter of the supernatant was used for PCR.
The cyp51A gene was ampliﬁed by PCR using two cyp51A primers (5=-GAGCCGAATGAAAGTTGCCTA
ATTACTA-3= and 5=-CCACAGTTTAGATAGGCTAGAAGGAG-3=). PCR was performed in a 50-l volume
containing 5 l buffer (ThermoPol reaction buffer; New England BioLabs), 1 l deoxynucleoside triphos-
phates (dNTPs) at 10 mM, 1 l of each primer at 100 M, 0.5 l Taq polymerase at 5,000 U/ml (New
England BioLabs), and 1 l of lysed supernatant containing genomic DNA. PCR products were puriﬁed
using ExoSAP-IT reagent (Affymetrix). Five microliters of the PCR product was mixed with 2 l of
ExoSAP-IT reagent. The solution was incubated for 15 min at 37°C, followed by a 15-min incubation
at 80°C.
PCR products were next sequenced using two sets of primers: CYP51A-A7 (5=-TCATATGTTGCTC
AGCGG-3=) and CYP51A-A5 (5=-TCTCTGCACGCAAAGAAGAAC-3=) for tandem repeat detection and
Cyp51a_sq3 (5=-CATGTGCGCAATCTCTTTATC-3=) and Cyp51a_q4 (5=-CGGAAGATAGGGACTTGACGT-3=) for
single-site mutation detection. Sequencing used the BigDye Terminator kit (Applied Biosystems, USA).
The sequences were analyzed using Geneious software, version 9.16 (Biomatters, New Zealand).
The A. fumigatus -tubulin gene was ampliﬁed with primers tubulin_s (5=-GCTCTGGCCACTACAATG
GCT-3=) and tubulin_as (5=-GTCCATGGTACCAGGCTCGA-3=). Gene products were puriﬁed and sequenced
as described above.
CSP1 typing. A. fumigatus isolates were genotyped by CSP1 typing. This subtyping strategy employs
comparative DNA sequence analysis of the tandem repeat region of the AFUA_3G08890 gene (17). The
CSP1 gene was ampliﬁed by PCR using two CSP1 primers proposed by Klaassen et al. (17): 5=-TTGGGT
GGCATTGTGCCAA-3= and 5=-GAGCATGACAACCCAGATACCA-3=. After PCR, the products were sequenced
as described above using the same primers as those used for the ampliﬁcation. Geneious software was
used to analyze results.
Case reports. Case 1 concerns a 52-year-old woman. She was diagnosed with homozygous Phe-
508del mutation CF when she was 38 years old. She is known to have severe airﬂow obstruction
(predicted forced expiratory volume in 1 second [FEV1] value, 31%) with severe diffuse bronchiectasis
and chronic infection by methicillin-susceptible Staphylococcus aureus (MSSA), Achromobacter xylosoxi-
dans, and Stenotrophomonas maltophilia. This chronic respiratory infection is complicated by acute
respiratory exacerbations necessitating intravenous antibiotic cures 2 to 3 times per year. Additionally,
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she recently received a successful 18-month course of antimycobacterial medication (rifabutin, clarithro-
mycin, and ethambutol) for Mycobacterium avium-associated pulmonary disease. She has demonstrated
chronic respiratory colonization with A. fumigatus since CF diagnosis but has never developed active
Aspergillus infection or ABPA. Her total IgE level is undetectable. She has never received antifungal
therapy, including triazoles. Her regular treatment is based on oral pancreatin, liposoluble vitamin
supplementation, and ursodeoxycholic acid and inhaled budesonide, formoterol, and dornase alpha. In
addition, she follows a twice-weekly physical treatment program for respiratory secretion drainage with
a physiotherapist. Since the patient is already presenting severe alteration in lung function, which is still
declining, double lung transplantation will be considered mandatory in the coming years.
Case 2 concerns a 27-year-old man. He was diagnosed with homozygous Phe-508del mutation CF
when he was born due to meconium ileus, requiring surgery. He is known to have stable mild airﬂow
obstruction (predicted FEV1 value, 82%) and mild diffuse bronchiectasis with chronic respiratory colo-
nization by MSSA, Stenotrophomonas maltophilia, and Haemophilus inﬂuenzae. Acute respiratory exac-
erbations are treated with an oral course of antibiotics against MSSA 1 to 2 times per year. He has
demonstrated new chronic respiratory colonization with A. fumigatus since January 2016. He has never
developed active aspergillus infection or ABPA. His total IgE level measurements have remained between
15 and 21.9 kU/liter during the past 24 months (normal value, 100 kU/liter). He has never received
antifungal therapy, including triazoles. His treatment is based on oral pancreatin, liposoluble vitamin
supplementation, and ursodeoxycholic acid and inhaled ﬂuticasone propionate and salbutamol. In
addition, he follows a weekly physical treatment program for respiratory secretion drainage with a
physiotherapist.
SUPPLEMENTAL MATERIAL
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